Characteristics | Epilepsy Cases | AEDs resistant group | AEDs responders | p value | |||
---|---|---|---|---|---|---|---|
Genotypes | AG(n = 244) | AA(n = 82) | AG(n = 120) | AA(n = 43) | AG(n = 124) | AA (n = 39) | |
Family historya |  |  |  |  |  |  | p1 = 0.268 |
 Negative | 150(61.5) | 56(68.3) | 60(50) | 32(74.4) | 90(72.6) | 24(61.5) | p2 = 0.006* |
 Positive | 94(38.5) | 26(31.7) | 60(50) | 11(25.6) | 34(27.4) | 15(38.5) | p3 = 0.19 |
Types of seizuresa | |||||||
 Tonic-clonic | 176(72.1) | 52(63.4) | 97(80.8) | 27(62.8) | 79(63.7) | 25(64.1) | p1 = 0.002* |
 Tonic | 25(10.2) | 19(23.2) | 0 | 10(23.3) | 25(20.2) | 9(23.1) | p2 < 0.001* |
 Myoclonic | 6(2.5) | 6(7.3) | 6(5) | 6(14) | 0 | 0 | p3 = 0.262 |
 Clonic | 10(4.1) | 0 | 0 | 0 | 10(8.1) | 0 | |
 Absence | 27(11.1) | 5(6.1) | 17(14.2) | 0 | 10(8.1) | 5(12.8) | |
EEGa | |||||||
 Normal | 60(24.6) | 46(56.1) | 11(9.1) | 22(51.2) | 49(39.5) | 24(61.5) | p1 < 0.001* |
 Generalized epileptiform activity | 184(75.4) | 36(43.9) | 109(90.9) | 21(48.8) | 75(60.5) | 15(38.5) | p2 < 0.001* p3 = 0.016* |
AEDs a | |||||||
 Topiramate | 12(4.9) | 0 | 12(10) | 0 | 0 | 0 | p1 = 0.04* p2 = 0.03* |
 Carbamazepine /Oxcarbazepine | 50(20.5) | 22(26.8) | 11(9.2) | 17(39.5) | 39(31.5) | 5(12.8) | p1 = 0.231 p2 = 0.03* p3 = 0.02* |
 Levetiracetam | 86(35.2) | 25(30.5) | 48(40) | 20(46.5) | 38(30.6) | 5(12.8) | p1 = 0.432 p2 = 0.457 p3 = 0.028* |
 Valproic acid | 215(88.1) | 66(80.5) | 115(95.8) | 32(74.4) | 100(80.6) | 34(87.2) | p1 = 0.083 p2 < 0.001* p3 = 0.352 |
Duration since the last seizure (months)b | 3(0.75–5) | 3(0.94–9) | 2(1–6) | 3(0.75–3) | 18(12–24) | 13(12–24) | p1 = 0.088 p2 = 0.029* p3 = 0.139 |
Age of the first seizure attack (years)b | 2(1–5) | 1(0.33–3) | 3(0.75–6) | 3(1–9) | 3(1–5) | 2.5(0.67–8) | p1 = 0.015* p2 = 0.03* p3 = 0.229 |
Frequency of seizures (per month)b | 13(12–24) | 12(6–24) | 2(1–5) | 1(0.33–4) | 0 | 0.17(0.17–0.17) | p1 = 0.004* p2 = 0.05* |